Brenton L. Saunders
| Brenton L. Saunders | |
|---|---|
| Born | February 6, 1970 Arizona, US |
| 🏫 Education | Parkland High School |
| 🎓 Alma mater | University of Pittsburgh Temple University |
| 💼 Occupation | Businessman |
| Title | CEO, Vesper Healthcare Acquisition |
| Term | 2014- |
| 👩 Spouse(s) | Married |
| 👶 Children | 2 daughters |
Brenton L. Saunders, also known as Brent Saunders (born February 6, 1970), is the CEO of Vesper Healthcare Acquisition Corp. He was previously CEO of the pharmaceutical company Allergan,[1] the CEO and president of Forest Laboratories, and the CEO of Bausch + Lomb Incorporated.
Early life[edit]
Saunders was born in Arizona on February 6, 1970,[2] the son of Charles Saunders, a retired urologist, and his wife Sheila. He has a twin brother Wayne and a sister Reed, and they grew up in South Whitehall, Pennsylvania. His mother co-founded Senior Solutions, the first geriatric-care management agency in Lehigh Valley. His father is chair of the board of trustees of St. Luke's University Health Network.[3]
Saunders graduated from Parkland High School in 1988.[3] He received a BA in economics and east Asian studies from the University of Pittsburgh in 1992, an MBA from Temple University Fox School of Business and Management in 1996, and a JD from Temple University Beasley School of Law in 1996.[4]
Career[edit]
1995–2000[edit]
He was the chairman of the New York chapter of the American Heart Association. He was on the transition team for New Jersey Governor-elect Chris Christie. He was the chief compliance officer for Coventry Health Care and for Thomas Jefferson University and Health System. He was senior vice president of compliance, legal, and regulatory at Home Care Corp. of America. He was the chief risk officer of Coventry Health Care from 1998 to 1999.[5]
2000–2010[edit]
Saunders was a partner and head of the compliance business advisory group at PricewaterhouseCoopers LLP from 2000 to 2003. He joined Schering-Plough from PricewaterhouseCoopers, where he led its compliance business advisory services group. He was a senior executive of Schering-Plough from 2003 to 2010 and its president of Global Consumer Health Care. He was the head of integration for Schering-Plough's merger with Merck & Co.[6]
2010 to present[edit]
Saunders was CEO of Bausch & Lomb from February 2010 to August 2013. While at Bausch & Lomb, he led the company to a sales growth of 9% a year and oversaw the introduction of 34 new products before its acquisition by Valeant Pharmaceuticals in 2013 for $8.7 billion.[7] He was then CEO of Forest Laboratories from October 2013 until its merger with Actavis Plc in 2014, where he stayed as CEO until he acquired Allergan in 2015 and renamed the entire corporation Allergan Plc.[8][9][10] He was chairman, president and CEO of Allergan Plc until May 2020.[11] He created the "Allergan Social Contract with Patients", with the stated aim of prohibiting price gouging and offering better patient access to Allergan medicines.[12]
He is the CEO of Vesper Healthcare Acquisition Corp.[13][14] He is an independent director of BridgeBio Pharma.[15]
Affiliations[edit]
Saunders is on the board of directors of Cisco Systems and RWJBarnabas Health, and is a member of the Business Council and PhRMA.[16] He is the former chairman of the New York chapter of the American Heart Association. He has been a director of Actavis Plc since July 2014. He is on the board of the Overlook Hospital Foundation.[17]
Personal life[edit]
He is married and has two daughters.[2]
References[edit]
- ↑ "Brent Saunders, Allergan PLC: Profile and Biography". Bloomberg.com. Retrieved 2021-03-02.
- ↑ 2.0 2.1 "The Botox initiation of Brent Saunders, Actavis chief executive". Financial Times. 17 May 2015. Retrieved 24 November 2015.
- ↑ 3.0 3.1 Harris, Jon (19 October 2015). "Brent Saunders, Parkland grad, is the Lehigh Valley's $150 billion dealmaker". The Morning Call. Retrieved 24 November 2015.
- ↑ "Teva Pharmaceutical Industries Ltd". www.tevapharm.com.
- ↑ Editorial, Reuters. "Officer Profile | Quotes | Reuters.co.in". IN.[dead link]
- ↑ Harris, Jon (October 19, 2015). "Brent Saunders, Parkland grad, is the Lehigh Valley's $150 billion dealmaker". The Morning Call.
- ↑ Euan Rocha, Rod Nickel (May 27, 2013). "Drugmaker Valeant to buy Bausch & Lomb for $8.7 billion". Reuters.
- ↑ Haggerty, Neil (June 15, 2015). "Actavis Changes Name to Allergan After Deal For Botox Maker". The Wall Street Journal.
- ↑ Staff (September 10, 2013). "Forest Labs names ex-Bausch & Lomb head Saunders as CEO". Reuters.
- ↑ Caroline Humer, Esha Dey (February 18, 2014). "Actavis to buy Forest for $25 billion; windfall for investor Icahn". Reuters.
- ↑ Taylor, Phil (2020-05-06). "Saunders steps aside as AbbVie closes in on Allergan merger -". pharmaphorum.com. Retrieved 2020-09-28.
- ↑ Mukherjee, Sy (September 6, 2016). "Allergan's CEO Just Pledged a 'Social Contract' With Patients on Drug Prices". Fortune.
- ↑ Taylor, Phil (2020-09-11). "Ex-Allergan CEO Saunders pops up again in 'blank cheque' company -". pharmaphorum.com. Retrieved 2020-09-28.
- ↑ Alpher, SA Editor Stephen (2020-09-11). "Allergan's ex-CEO Brent Saunders launching blank-check company (NYSE:ABBV)". Seeking Alpha. Retrieved 2020-09-28.
- ↑ "Saunders finds life after Allergan on board at newly IPO'ed BridgeBio". FiercePharma. 24 June 2020. Retrieved 2020-09-28.
- ↑ "Board of Directors". Cisco official website.
- ↑ "Executive Profile* Brenton L. Saunders J.D." Bloomberg L.P. Retrieved 24 November 2015.
This article "Brenton L. Saunders" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Brenton L. Saunders. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
- 1970 births
- American chief executives
- Businesspeople in the pharmaceutical industry
- Chief executives in the pharmaceutical industry
- University of Pittsburgh alumni
- Temple University Beasley School of Law alumni
- Fox School of Business and Management alumni
- Parkland High School (Allentown, Pennsylvania) alumni
